Patent ID: 8435489

Claim:
A method of diagnosing the existence of a disease state or condition in tissue of a patient in which levels of LFA-1 or ICAM receptors are suspected of being elevated comprising administering to said patient an effective amount of at least one compound according to the following chemical structure: wherein Y is a —(CH 2 ) n Z— group where n is 4, Z is a NR group and R is H, and which group links the nitrogen of said NR group to a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group and wherein said DOTA group incorporates or complexes with a radioisotope selected from the group consisting of 90 Y, 111 In, 177 Lu, 67 Ga, 68 Ga, and 213 Bi, or a pharmaceutically acceptable salt thereof, measuring the amount of said compound which binds to said tissue in said patient, and comparing said measurement from said measuring step with a standard, wherein an elevated measurement in comparison to said standard is indicative of the existence of said disease state or condition in said patient and said disease state or condition is an inflammatory disease, an autoimmune disease or a hyperproliferative disease, wherein said inflammatory disease is arthritis, rheumatoid arthritis or osteoarthritis, adult respiratory distress syndrome, shock, oxygen toxicity, septic shock, multiple organ injury syndrome secondary to septicemia or multiple organ injury syndrome secondary to trauma, said autoimmune disease is Raynaud's syndrome, autoimmune thyroiditis, dermatitis, multiple sclerosis, insulin-dependent diabetes mellitus, diabetes retinopathy, uveitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis or systemic lupus erythematosus and said hyperproliferative disease is psoriasis, hyperkeratosis, ichthyoisis, keratoderma, lichen planus or warts.